Objective: To evaluate the clinical efficacy, operability, radicality,
toxicity, and incidence of recurrences of neoadjuvant chemotherapy
(NAC) followed by radical hysterectomy (RH) among patients with
stage IIB cervical cancer.
Method: This is an observational clinical study at Dr. Moh. Hoesin
Hospital, Palembang. Data were analyzed from 27 patients who
matched the inclusion criteria and underwent 3 cycles of neoadjuvant
chemotherapy (NAC) with Paclitaxel (75 mg/m2) in combination
with Cisplatin (50 mg/m2) and Docetaxel (75 mg/m2) combined
with Carboplatin (300 mg/m2) according to AUC 6, followed by radical
hysterectomy from January 2012 until December 2013.
Result: The operability rate after NAC was 96.4%. Lymph node metastases
were negative in 75% of patients, and we found bilateral
lymph node metastases in 14.3% of patients. Parametric infiltrations
were negative in 85.7% of the patients, and positive in 14.3% of patients.
No vaginal infiltrations were found. As much as 89.3% of the
patients did not experience any side effect, while anemia and thrombocytopenia
were found in 10.8% of the patients. We found that
7.1% of patients had recurrences within 6 months interval.
Conclusion: NAC followed by radical hysterectomy showed significant
advantages for patients with stage IIB cervical cancer, with
fewer side effects. However, long-term evaluation and a larger number
of patients are required to confirm this result.
Keywords: cervical cancer, neoadjuvant chemotherapy, radical hysterectomy
Association of Insurance Status and Age With Cervical Cancer Stage at Diagnosis: National Cancer Database, 2000–2007